Inhibikase Therapeutics IKT
NASDAQ IKT
$1.59 -0.04 (-2.76%)
As of: Oct 23, 2026 · 1:52 PM EDT

Inhibikase Therapeutics (IKT) Total Non-Current Liabilities (2024 - 2026)

Updated

Inhibikase Therapeutics' Total Non-Current Liabilities was $9.86 million in Q2 2026, up 85.6% from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends

From Q1 2024 onward, Inhibikase Therapeutics has reported Total Non-Current Liabilities for 4 quarters.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,132.13 Bn 1,100.72 Bn 19.71 Bn 60.66 Bn
2 Johnson & Johnson 634.87 Bn 554.73 Bn 17.30 Bn 102.65 Bn
3 AbbVie 506.59 Bn 479.70 Bn 12.70 Bn 106.45 Bn
4 Merck 357.59 Bn 311.97 Bn 12.21 Bn 80.25 Bn
5 Novartis Ag 291.51 Bn 255.50 Bn 11.24 Bn 48.34 Bn
6 Astrazeneca 265.00 Bn 238.69 Bn 12.86 Bn 33.91 Bn
7 Amgen 238.17 Bn 193.57 Bn 7.24 Bn 78.66 Bn
8 Gilead Sciences 195.18 Bn 169.37 Bn 6.22 Bn 35.10 Bn
9 Pfizer 171.20 Bn 117.84 Bn 10.94 Bn 97.04 Bn
10 Inhibikase Therapeutics 276.70 Mn -308.78 Mn - 9.86 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 9.86 Mn
Mar 31, 2026 5.31 Mn
Mar 31, 2025 4.12 Mn
Mar 31, 2024 4.29 Mn
API Access

Inhibikase Therapeutics Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=IKT&period=max&api_key=YOUR_API_KEY